Impaired  ||| S:0 E:9 ||| NNP
FEF25-75  ||| S:9 E:18 ||| NNP
may  ||| S:18 E:22 ||| MD
predict  ||| S:22 E:30 ||| VB
high  ||| S:30 E:35 ||| JJ
exhaled  ||| S:35 E:43 ||| JJ
nitric  ||| S:43 E:50 ||| JJ
oxide  ||| S:50 E:56 ||| NN
values  ||| S:56 E:63 ||| NNS
in  ||| S:63 E:66 ||| IN
children  ||| S:66 E:75 ||| NNS
with  ||| S:75 E:80 ||| IN
allergic  ||| S:80 E:89 ||| JJ
rhinitis  ||| S:89 E:98 ||| NN
and ||| S:98 E:101 ||| CC
/ ||| S:101 E:102 ||| NNP
or  ||| S:102 E:105 ||| CC
asthma  ||| S:105 E:112 ||| JJ
Allergic  ||| S:112 E:121 ||| JJ
rhinitis  ||| S:121 E:130 ||| NN
and  ||| S:130 E:134 ||| CC
asthma  ||| S:134 E:141 ||| NNS
are  ||| S:141 E:145 ||| VBP
closely  ||| S:145 E:153 ||| RB
associated ||| S:153 E:163 ||| VBN
.  ||| S:163 E:165 ||| .
Inflammation  ||| S:165 E:178 ||| NNP
is  ||| S:178 E:181 ||| VBZ
a  ||| S:181 E:183 ||| DT
common  ||| S:183 E:190 ||| JJ
pathological  ||| S:190 E:203 ||| NNS
characteristic  ||| S:203 E:218 ||| VBP
shared  ||| S:218 E:225 ||| VBN
by  ||| S:225 E:228 ||| IN
both  ||| S:228 E:233 ||| DT
disorders ||| S:233 E:242 ||| NNS
.  ||| S:242 E:244 ||| .
The  ||| S:244 E:248 ||| DT
measure  ||| S:248 E:256 ||| NN
of  ||| S:256 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
fractional  ||| S:263 E:274 ||| JJ
concentration  ||| S:274 E:288 ||| NN
of  ||| S:288 E:291 ||| IN
exhaled  ||| S:291 E:299 ||| FW
nitric  ||| S:299 E:306 ||| FW
oxide  ||| S:306 E:312 ||| FW
( ||| S:312 E:313 ||| -LRB-
FeNO ||| S:313 E:317 ||| NNP
)  ||| S:317 E:319 ||| -RRB-
may  ||| S:319 E:323 ||| MD
be  ||| S:323 E:326 ||| VB
considered  ||| S:326 E:337 ||| VBN
a  ||| S:337 E:339 ||| DT
surrogate  ||| S:339 E:349 ||| JJ
marker  ||| S:349 E:356 ||| NN
for  ||| S:356 E:360 ||| IN
airway  ||| S:360 E:367 ||| JJ
inflammation ||| S:367 E:379 ||| NN
.  ||| S:379 E:381 ||| .
Forced  ||| S:381 E:388 ||| VBN
expiratory  ||| S:388 E:399 ||| JJ
flow  ||| S:399 E:404 ||| NN
between  ||| S:404 E:412 ||| IN
25  ||| S:412 E:415 ||| CD
and  ||| S:415 E:419 ||| CC
75  ||| S:419 E:422 ||| CD
percent  ||| S:422 E:430 ||| NN
of  ||| S:430 E:433 ||| IN
vital  ||| S:433 E:439 ||| JJ
capacity  ||| S:439 E:448 ||| NN
( ||| S:448 E:449 ||| -LRB-
FEF25-75 ||| S:449 E:457 ||| NNP
)  ||| S:457 E:459 ||| -RRB-
has  ||| S:459 E:463 ||| VBZ
been  ||| S:463 E:468 ||| VBN
previously  ||| S:468 E:479 ||| RB
demonstrated  ||| S:479 E:492 ||| VBN
to  ||| S:492 E:495 ||| TO
be  ||| S:495 E:498 ||| VB
able  ||| S:498 E:503 ||| JJ
to  ||| S:503 E:506 ||| TO
predict  ||| S:506 E:514 ||| VB
BHR  ||| S:514 E:518 ||| NNP
and  ||| S:518 E:522 ||| CC
bronchial  ||| S:522 E:532 ||| JJ
reversibility ||| S:532 E:545 ||| NN
.  ||| S:545 E:547 ||| .
The  ||| S:547 E:551 ||| DT
aim  ||| S:551 E:555 ||| NN
of  ||| S:555 E:558 ||| IN
this  ||| S:558 E:563 ||| DT
study  ||| S:563 E:569 ||| NN
was  ||| S:569 E:573 ||| VBD
to  ||| S:573 E:576 ||| TO
evaluate  ||| S:576 E:585 ||| VB
whether  ||| S:585 E:593 ||| IN
impaired  ||| S:593 E:602 ||| CD
FEF25-75  ||| S:602 E:611 ||| CD
values  ||| S:611 E:618 ||| NNS
may  ||| S:618 E:622 ||| MD
be  ||| S:622 E:625 ||| VB
related  ||| S:625 E:633 ||| VBN
to  ||| S:633 E:636 ||| TO
FeNO  ||| S:636 E:641 ||| JJ
values  ||| S:641 E:648 ||| NNS
in  ||| S:648 E:651 ||| IN
a  ||| S:651 E:653 ||| DT
pediatric  ||| S:653 E:663 ||| JJ
cohort  ||| S:663 E:670 ||| NN
of  ||| S:670 E:673 ||| IN
allergic  ||| S:673 E:682 ||| CD
subjects.  ||| S:682 E:692 ||| CD
850  ||| S:692 E:696 ||| CD
children  ||| S:696 E:705 ||| NNS
with  ||| S:705 E:710 ||| IN
allergic  ||| S:710 E:719 ||| JJ
rhinitis ||| S:719 E:727 ||| NN
,  ||| S:727 E:729 ||| ,
allergic  ||| S:729 E:738 ||| JJ
asthma ||| S:738 E:744 ||| NN
,  ||| S:744 E:746 ||| ,
or  ||| S:746 E:749 ||| CC
both ||| S:749 E:753 ||| DT
,  ||| S:753 E:755 ||| ,
were  ||| S:755 E:760 ||| VBD
evaluated ||| S:760 E:769 ||| VBN
.  ||| S:769 E:771 ||| .
Bronchial  ||| S:771 E:781 ||| JJ
function  ||| S:781 E:790 ||| NN
( ||| S:790 E:791 ||| -LRB-
FEV1 ||| S:791 E:795 ||| NNP
,  ||| S:795 E:797 ||| ,
FVC ||| S:797 E:800 ||| NNP
,  ||| S:800 E:802 ||| ,
and  ||| S:802 E:806 ||| CC
FEF25-75 ||| S:806 E:814 ||| CD
) ||| S:814 E:815 ||| -RRB-
,  ||| S:815 E:817 ||| ,
FeNO ||| S:817 E:821 ||| NNP
,  ||| S:821 E:823 ||| ,
and  ||| S:823 E:827 ||| CC
sensitizations  ||| S:827 E:842 ||| NNS
were  ||| S:842 E:847 ||| VBD
assessed ||| S:847 E:855 ||| VBN
.  ||| S:855 E:857 ||| .
Bronchial  ||| S:857 E:867 ||| JJ
function  ||| S:867 E:876 ||| NN
and  ||| S:876 E:880 ||| CC
FeNO  ||| S:880 E:885 ||| NNP
were  ||| S:885 E:890 ||| VBD
significantly  ||| S:890 E:904 ||| RB
different  ||| S:904 E:914 ||| JJ
in  ||| S:914 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
3  ||| S:921 E:923 ||| CD
groups  ||| S:923 E:930 ||| NNS
( ||| S:930 E:931 ||| -LRB-
p  ||| S:931 E:933 ||| RB
less  ||| S:933 E:938 ||| JJR
than  ||| S:938 E:943 ||| IN
0.001 ||| S:943 E:948 ||| CD
) ||| S:948 E:949 ||| -RRB-
.  ||| S:949 E:951 ||| .
A  ||| S:951 E:953 ||| DT
strong  ||| S:953 E:960 ||| JJ
inverse  ||| S:960 E:968 ||| JJ
correlation  ||| S:968 E:980 ||| NN
between  ||| S:980 E:988 ||| IN
FeNO  ||| S:988 E:993 ||| JJ
and  ||| S:993 E:997 ||| CC
FEV1was  ||| S:997 E:1005 ||| NNP
found  ||| S:1005 E:1011 ||| VBD
in  ||| S:1011 E:1014 ||| IN
patients  ||| S:1014 E:1023 ||| NNS
with  ||| S:1023 E:1028 ||| IN
rhinitis ||| S:1028 E:1036 ||| NN
,  ||| S:1036 E:1038 ||| ,
asthma  ||| S:1038 E:1045 ||| NN
and  ||| S:1045 E:1049 ||| CC
asthma  ||| S:1049 E:1056 ||| NN
with  ||| S:1056 E:1061 ||| IN
rhinitis  ||| S:1061 E:1070 ||| NNS
( ||| S:1070 E:1071 ||| -LRB-
r=  ||| S:1071 E:1074 ||| NNP
-0.72 ||| S:1074 E:1079 ||| NNP
,  ||| S:1079 E:1081 ||| ,
r=-0.70  ||| S:1081 E:1089 ||| NNP
and  ||| S:1089 E:1093 ||| CC
r=  ||| S:1093 E:1096 ||| NNP
-0.70 ||| S:1096 E:1101 ||| NNP
,  ||| S:1101 E:1103 ||| ,
respectively ||| S:1103 E:1115 ||| RB
) ||| S:1115 E:1116 ||| -RRB-
.  ||| S:1116 E:1118 ||| .
Impaired  ||| S:1118 E:1127 ||| NNP
FEF25-75  ||| S:1127 E:1136 ||| NNP
values  ||| S:1136 E:1143 ||| NNS
( ||| S:1143 E:1144 ||| -LRB-
such  ||| S:1144 E:1149 ||| JJ
as  ||| S:1149 E:1152 ||| IN
less  ||| S:1152 E:1157 ||| JJR
than  ||| S:1157 E:1162 ||| IN
65  ||| S:1162 E:1165 ||| CD
percent  ||| S:1165 E:1173 ||| NN
of  ||| S:1173 E:1176 ||| IN
predicted ||| S:1176 E:1185 ||| CD
)  ||| S:1185 E:1187 ||| -RRB-
were  ||| S:1187 E:1192 ||| VBD
significantly  ||| S:1192 E:1206 ||| RB
associated  ||| S:1206 E:1217 ||| VBN
with  ||| S:1217 E:1222 ||| IN
high  ||| S:1222 E:1227 ||| JJ
FeNO  ||| S:1227 E:1232 ||| JJ
levels  ||| S:1232 E:1239 ||| NNS
( ||| S:1239 E:1240 ||| -LRB-
such  ||| S:1240 E:1245 ||| JJ
as  ||| S:1245 E:1248 ||| IN
=34  ||| S:1248 E:1252 ||| CD
ppb ||| S:1252 E:1255 ||| CD
) ||| S:1255 E:1256 ||| -RRB-
.  ||| S:1256 E:1258 ||| .
In  ||| S:1258 E:1261 ||| IN
conclusion ||| S:1261 E:1271 ||| NN
,  ||| S:1271 E:1273 ||| ,
this  ||| S:1273 E:1278 ||| DT
study  ||| S:1278 E:1284 ||| NN
provided  ||| S:1284 E:1293 ||| VBD
evidence  ||| S:1293 E:1302 ||| NN
that  ||| S:1302 E:1307 ||| IN
FEF25-75  ||| S:1307 E:1316 ||| NNP
is  ||| S:1316 E:1319 ||| VBZ
strongly  ||| S:1319 E:1328 ||| RB
and  ||| S:1328 E:1332 ||| CC
inversely  ||| S:1332 E:1342 ||| RB
related  ||| S:1342 E:1350 ||| VBN
with  ||| S:1350 E:1355 ||| IN
FeNO  ||| S:1355 E:1360 ||| JJ
and  ||| S:1360 E:1364 ||| CC
FEF25-75  ||| S:1364 E:1373 ||| NNP
may  ||| S:1373 E:1377 ||| MD
predict  ||| S:1377 E:1385 ||| VB
high  ||| S:1385 E:1390 ||| JJ
FeNO  ||| S:1390 E:1395 ||| JJ
levels  ||| S:1395 E:1402 ||| NNS
in  ||| S:1402 E:1405 ||| IN
children  ||| S:1405 E:1414 ||| NNS
with  ||| S:1414 E:1419 ||| IN
allergic  ||| S:1419 E:1428 ||| JJ
rhinitis ||| S:1428 E:1436 ||| NN
,  ||| S:1436 E:1438 ||| ,
asthma  ||| S:1438 E:1445 ||| NN
or  ||| S:1445 E:1448 ||| CC
both ||| S:1448 E:1452 ||| DT
.  ||| S:1452 E:1454 ||| .
